AURKB and prostate carcinoma: At present, many studies have already indicated that AURKB is a promising therapeutic target in various cancers, such as non-small cell lung cancer (NSCLC) (Bertran-Alamillo et al., 2019), gastric cancer (GC) (He et al., 2019), leukemia (He et al., 2016), prostate cancer (PC) (Addepalli et al., 2010), and breast cancer (Han et al., 2017).